Source:http://linkedlifedata.com/resource/pubmed/id/19422339
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2009-5-8
|
| pubmed:abstractText |
The incidence and treatment of both systemic and pulmonary human cytomegalovirus (HCMV) infection as well as HCMV-specific T-cell immune responses were investigated in 57 consecutive lung transplant recipients (LTR) by using as cutoffs for preemptive therapy: 300 000 DNA copies/mL whole blood for systemic infections and 100 000 DNA copies/mL bronchoalveolar lavage fluid for lung infections. Results showed that out of 29/57 LTR (50.9%) needing preemptive antiviral therapy, 15 (51.7%) reached the blood cutoff, 8 (27.6%) the pulmonary cutoff and 6 (20.7%) both the blood and the lung cutoff (3 simultaneously and 3 subsequently). Recovery of HCMV-specific T-cell immune responses was achieved much earlier for CD8+ than CD4+ T cells. However, protection from HCMV reactivation was conferred by the presence of both arms of the T-cell response. In two LTR reaching the pulmonary cutoff and not preemptively treated, a full HCMV-specific CD4+ and CD8+ T-cell response was associated with resolution of lung infection. Antirejection steroid therapy suppressed T-cell immune responses, thus facilitating HCMV reactivation. In conclusion, in LTR, monitoring HCMV infection in both blood and lungs, may improve preemptive therapy efficacy. In addition, monitoring the HCMV-specific T-cell immune response appears useful for predicting control of HCMV infection in the posttransplant period.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
1600-6143
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1142-50
|
| pubmed:meshHeading |
pubmed-meshheading:19422339-Adolescent,
pubmed-meshheading:19422339-Adrenal Cortex Hormones,
pubmed-meshheading:19422339-Adult,
pubmed-meshheading:19422339-Aged,
pubmed-meshheading:19422339-CD4-Positive T-Lymphocytes,
pubmed-meshheading:19422339-CD8-Positive T-Lymphocytes,
pubmed-meshheading:19422339-Cytomegalovirus,
pubmed-meshheading:19422339-Cytomegalovirus Infections,
pubmed-meshheading:19422339-Female,
pubmed-meshheading:19422339-Heart-Lung Transplantation,
pubmed-meshheading:19422339-Humans,
pubmed-meshheading:19422339-Immunosuppression,
pubmed-meshheading:19422339-Lung Diseases,
pubmed-meshheading:19422339-Lung Transplantation,
pubmed-meshheading:19422339-Male,
pubmed-meshheading:19422339-Middle Aged,
pubmed-meshheading:19422339-Pneumonia, Viral,
pubmed-meshheading:19422339-Postoperative Complications,
pubmed-meshheading:19422339-T-Lymphocytes,
pubmed-meshheading:19422339-Young Adult
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients.
|
| pubmed:affiliation |
Servizio di Virologia, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy. g.gerna@smatteo.pv.it
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|